Quality key factors
Factor
Value
Sales Growth (5y)
495.40%
EBIT Growth (5y)
-39.44%
EBIT to Interest (avg)
-440.43
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.02
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.52
EV to EBIT
-9.98
EV to EBITDA
-10.52
EV to Capital Employed
8.06
EV to Sales
178.08
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-80.79%
ROE (Latest)
-39.47%
Not enough Data to analyse Financial Trend
Not enough Data to analyse Financial Trend
Here's what is working for Xuanzhu Biopharmaceutical Co., Ltd.
Pre-Tax Profit
Highest at HKD -119.13 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (HKD MM)
Net Profit
Highest at HKD -119.13 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (HKD MM)
EPS
Highest at HKD -0.23
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (HKD)
Raw Material Cost
Fallen by -577% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales






